Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

NCT06280313 is registered in ClinicalTrials.gov with Zhiyong Huang as lead sponsor.

NCT NCT06280313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06280313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
Lead sponsor
Zhiyong Huang
Phase
Observational
Overall status
Recruiting
Start date
March 15, 2024
Completion date
March 15, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma